A rare case of uterine leiomyosarcoma: a case report by Vellanki, Venkata Sujatha et al.
CASE REPORT Open Access
A rare case of uterine leiomyosarcoma:
a case report
Venkata Sujatha Vellanki
*, Meghana Rao, Chinna Babu Sunkavalli, Rao N Chinamotu, Shailaja Kaja
Abstract
Introduction: Malignant change in a leiomyoma or uterine fibroid is termed leiomyosarcoma. It arises from smooth
muscle of the uterus and is a rare tumor that accounts for 2% to 5% of all uterine malignancies. Very few cases are
reported in the literature. Our patient did not have any history of genital bleeding, which is the usual presentation
in uterine sarcoma. We report an original case report of an unusual presentation of this rare tumor arising from the
uterus.
Case presentation: A 40-year-old nulliparous woman of South Indian origin presented with a mass in her
abdomen for one year with a rapid increase in size over the previous three months. Tumor marker CA-125 was
raised, and a computed tomography scan showed a mass arising from the pelvis. An exploratory laparotomy was
performed and the histopathology report confirmed the diagnosis of uterine leiomyosarcoma.
Conclusion: Because of their rarity, uterine sarcomas are not suitable for screening. Diagnosis is by histopathologic
examination and surgery is the only treatment. The prognosis for women with uterine sarcoma primarily depends
on the extent of disease at the time of diagnosis and the mitotic index.
Introduction
Malignant change in a leiomyoma or uterine fibroid is
termed leiomyosarcoma. It arises from smooth muscle
of the uterus and is a rare tumor that accounts for 2%
to 5% of all uterine malignancies [1].
Case report
A 40-year-old nulliparous woman of South Indian origin
reported to our outpatient clinic with complaints of a
mass in the lower abdomen for one year and lower
abdominal pain for three months. The patient was
apparently asymptomatic one year previously, and then
she noticed a mass in the lower abdomen that gradually
increased in size. She provided a history of a rapid
increase in size for the past three months. She also had
associated lower abdominal pain, which was dull and
aching in type, dragging in nature and continuous with
no aggravating or relieving factors. Her menstrual cycles
were regular and normal. She had no history of genital
bleeding.
On examination, pallor was present, and the patient’s
vital signs were normal. She was thinly built. On
abdominal examination, an irregular midline mass aris-
ing from the pelvis was present. The upper and lateral
borders of the mass could be made out; the lower mar-
gin could not be ascertained. The mass was firm to hard
in consistency with restricted mobility and nontender
with no free fluid. There was no hepatosplenomegaly.
On vaginal examination, the patient’su t e r u sw a s
enlarged to 20 weeks’ gestational size and nodular, occu-
pying the whole pelvis. No mass could be appreciated
separate from uterus. Computed tomography (CT) scan
findings were suggestive of a large, multiloculated, mul-
tiseptate growth containing both solid and cystic ele-
ments arising from the pelvis and extending into the
abdomen, measuring 25 × 17 cm, adherent to both the
uterus and bladder. CA125 was 94.80 ng/mL (0-35 ng/
mL). Other results were normal, and the patient was
posted for exploratory laparotomy.
Intraoperatively, omental adhesions to the mass were
noticed. A mass of 20 weeks’ size was arising from the
fundus of the uterus (Figure 1). It was lobulated (Figure
2) with solid, cystic and hemorrhagic components. Both * Correspondence: sujathavv@yahoo.com
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edematous (Figure 3).
Total abdominal hysterectomy (along with tumor)
with bilateral salpingo oophorectomy was done (Figure
4). The uterus measured 8 cm × 5 cm × 3 cm with a
subserosal bosselated growth from the fundus measuring
18 cm × 15 cm × 11 cm with variable consistency.
Omental biopsy and external iliac lymph node biopsy
were taken and sent for histopathologic examination.
Histopathologic examination showed a cellular tumor
arranged in interlacing bundles of spindle cells with
elongated hyperchromatic nuclei. The tumor cells were
exhibiting moderate pleomorphism and bizarre nuclei
with multinucleate tumor giant cells. There were scat-
tered areas and normal and abnormal mitotic figures
(> 4/high-power field) with marked nuclear atypia sug-
gestive of uterine leiomyosarcoma (Figure 5). The
omentum and external iliac lymph node were free from
tumor cells.
Discussion
Uterine sarcomas are rare and constitute about 2% to
5% of all uterine malignancies [1]. Prior pelvic radiation
(10%-25% of cases) was considered to be a risk factor.
Data regarding parity and time of menarche and meno-
pause as risk factors are inconclusive. An increase in the
risk of uterine sarcomas appears to accompany the use
of long-term adjuvant tamoxifen in women with breast
cancer [2]. The incidence of sarcoma is 1% to 2% in
postmenopausal women. These patients usually present
with abnormal uterine bleeding [3]. Our patient did not
have any menstrual abnormalities. It is a rapidly growing
tumor with a doubling time of four weeks. The inci-
dence of mixed Müllerian sarcomas is 50% percent, leio-
myosarcoma is 30%, endometrial stromal sarcoma is
Figure 1 The uterus with a pedunculated tumor.
Figure 2 A lobulated mass arising from the uterine fundus.
Figure 3 The uterus, cervix, bilateral fallopian tubes and
ovaries and mass from fundus.
Figure 4 Cut sections of the uterus and the tumor.
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Page 2 of 315%, and adenosarcoma is 5%. The diagnosis of uterine
sarcomas is made from histologic examination of the
entire uterus.
Conclusion
Because of their rarity, uterine sarcomas are not suitable
for screening. Surgery is the only treatment. The prog-
nosis for women with uterine sarcoma primarily
depends on the extent of disease at the time of diagnosis
and the mitotic index [4].Women with tumor size more
than 5 cm in maximum diameter have a poor prognosis
[5].Nonrandomized studies have reported improved sur-
vival after adjuvant chemotherapy with or without radia-
tion therapy. The value of pelvic radiation therapy has
not been established. Current studies consist primarily
of phase II chemotherapy trials for patients with
advanced disease [6].
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Figure 5 Microscopic examination showing a cellular tumor
arranged in interlacing bundles of spindle cells with elongated
hyperchromatic nuclei and nuclear pleomorphism.
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